Stevenson Search Partners Fills Senior Post for Royalty Pharma
April 3, 2026 – Fort Lee, NJ-based Stevenson Search Partners, a global life science executive search firm and a Hunt Scanlon Top 50 ranked search firm, has assisted in the recruitment of Benjamin Olenchock as head of clinical sciences at Royalty Pharma. Dr. Olenchock joins Royalty Pharma’s research & investments team, bringing senior clinical and regulatory expertise to the firm’s investment process. “We’re pleased to share the appointment of Benjamin Olenchock, MD, PhD to head of clinical sciences at Royalty Pharma,” Stevenson Search Partners said in a LinkedIn post. “Ben brings senior clinical and regulatory expertise to the investment process at Royalty Pharma, the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation across the industry.”
Most recently, Dr. Olenchock served at Regeneron for nearly nine years, holding a series of progressively senior roles, from medical director through senior medical director and executive medical director, before serving as global program head. Prior to that, he completed his clinical training at Brigham and Women’s Hospital, where he was a resident physician in internal medicine and a clinical fellow in cardiovascular diseases and critical care medicine.
Dr. Olenchock then conducted research fellowships at Dana-Farber Cancer Institute, in the Kaelin Laboratory, and at the Massachusetts Institute of Technology, in the Vander Heiden Laboratory, before serving as associate physician and instructor in medicine at Brigham and Women’s Hospital and Harvard Medical School. Dr. Olenchock earned his doctor of medicine and doctor of philosophy in immunology from the University of Pennsylvania School of Medicine.
“It’s a privilege to support Royalty Pharma in advancing their partners’ core missions and, ultimately, driving progress across the biopharmaceutical landscape,” said Dr. Olenchock.
Royalty Pharma is a New York-based biopharmaceutical financing company that focuses on acquiring and managing royalty interests in pharmaceutical products. Rather than developing or manufacturing drugs itself, the firm invests in therapies by purchasing the rights to future revenues generated from approved or late-stage medicines. Founded in 1996, Royalty Pharma is considered a pioneer in the royalty funding model and works with a wide range of partners, including pharmaceutical companies, biotech firms, universities, and research institutions.
With more than 40 years of experience, Stevenson Search Partners serves the global biotechnology, pharmaceutical, medical technology, health technology, and CRO/CDMO sectors, with offices in the U.S. and the U.K. Founded in 1979, Stevenson’s expertise includes C-suite, research, clinical, development, commercial manufacturing, and corporate functions, and working with companies ranging from start-ups and academic spinouts to large pharma clients. Stevenson provides a collaborative, long-term approach to its clients with a global network and strategic talent mapping and pipelining, and competitive analysis services.
The search firm boasts an entrepreneurial and diversity-driven culture, with expansive industry expertise and broad international reach. In 2020, Stevenson expanded its operations with the opening of an office in the U.K., which also serves the E.U. and other regions, as part of its strategic growth in the global life science and healthcare area.
DaCapo Brainscience Search
Stevenson Search Partners also recently placed Leslie Williams as president and CEO of DaCapo Brainscience in Cambridge, MA. “From inception, our vision has been to address neurodegenerative diseases at the point of progression,” said Matthew Peck, co-founder, senior advisor, and former interim chief executive officer of DaCapo Brainscience. “We welcome Leslie to our company and look forward to the experience she brings as we transition to our next phase of growth.”
Ms. Williams joins DaCapo as an accomplished biotechnology entrepreneur and executive with a demonstrated track record of founding and scaling innovative biotech ventures that have advanced breakthrough science from discovery through commercialization. With over 25 years of experience building high-growth life science companies, she brings deep expertise in raising capital, developing corporate strategy, and guiding organizations through critical stages of growth and clinical development.
DaCapo Brainscience uses its own discovery platform to develop small-molecule medicines for neurodegenerative diseases. By combining advanced data analysis with human-based laboratory models, they identify new disease pathways and design targeted treatments that aim to slow or stop disease progression, with an initial focus on Parkinson’s disease.
Related: Stevenson Search Partners Receives Long-Term Investment from SixSibs Capital
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
